I n n o v a t i o © Mithra
n h n o l
The Mithra CDMO technology platform is notable for its development of long-term therapeutic solutions using medical polymers, with durations ranging from one month to five years. The solutions include a subcutaneous implant to treat prostate, breast and endometrial cancer. This is in line with the recommendation of the World Health Organization (WHO), that encourages the development of long acting therapeutic solutions to improve health outcomes, while reducing budgetary impact. Mithra will continue working with external partners to develop prolongedrelease solutions – a market that is even more promising because medical polymers are still insufficiently explored and under-used in important areas, such as oncology, contraception and infectious diseases.
c
The second pole of Mithra’s R&D activities relates to its Contract Development and Manufacturing Organization (CDMO) that focuses on three main areas: polymer technologies (rings, IUDs, implants), sterile injectable formulas (vials, cartridges, prefilled syringes) and hormonal tablets. From Proof-of-Concept to the first commercial batches, the flexible platform of Mithra CDMO provides a one-stop shop that is open to third parties requiring
T e
small to medium-sized batches. It also provides various services, including analysis, production, logistics, quality assurance, development and formulation.
State-of-the-art R&D and Manufacturing platform
o g
© Mithra
135
y
Mithra Pharmaceuticals Rue Saint-Georges 5-7 - 4000 Liège Tel.: +32 (0)4 349 28 22 - Fax: +32 (0)4 349 28 21 Email: info@mithra.com - https://www.mithra.com
